SUTRO BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.42 USD | 0.00% |
|
-5.79% | -20.28% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 254 | 987.9 | 688.5 | 464.4 | 261.5 | 263.1 | - | - |
| Enterprise Value (EV) 1 | 146 | 987.9 | 552 | 179.6 | 261.5 | 98.98 | -104.9 | 99.95 |
| P/E ratio | -4.53 x | -21.9 x | -6.5 x | -3.44 x | -2.41 x | -1.04 x | -1.05 x | -1.21 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.94 x | 23.1 x | 11.1 x | 6.85 x | 1.7 x | 3.67 x | 4.36 x | 2.84 x |
| EV / Revenue | 3.42 x | 23.1 x | 8.92 x | 2.65 x | 1.7 x | 1.38 x | -1.74 x | 1.08 x |
| EV / EBITDA | -2,880,268 x | - | -5,892,258 x | -1,457,131 x | - | - | - | - |
| EV / FCF | -2.13 x | -13.2 x | -5.69 x | -41.7 x | - | -0.41 x | 0.46 x | -0.5 x |
| FCF Yield | -46.9% | -7.58% | -17.6% | -2.4% | - | -241% | 217% | -200% |
| Price to Book | 2.6 x | - | - | - | - | -3.61 x | 4.62 x | -4.76 x |
| Nbr of stocks (in thousands) | 23,090 | 45,504 | 46,270 | 57,475 | 60,953 | 76,921 | - | - |
| Reference price 2 | 11.00 | 21.71 | 14.88 | 8.080 | 4.290 | 3.420 | 3.420 | 3.420 |
| Announcement Date | 3/16/20 | 3/18/21 | 2/28/22 | 3/30/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.74 | 42.72 | 61.88 | 67.77 | 153.7 | 71.73 | 60.34 | 92.69 |
| EBITDA | -50.69 | - | -93.68 | -123.3 | - | - | - | - |
| EBIT 1 | -55.47 | -71.06 | -98.52 | -128.9 | -89.28 | -214.4 | -256.3 | -243 |
| Operating Margin | -129.79% | -166.32% | -159.22% | -190.26% | -58.07% | -298.94% | -424.78% | -262.18% |
| Earnings before Tax (EBT) 1 | -55.74 | -32.13 | -105.5 | -116.7 | -88.6 | -217.2 | -260.2 | -249.6 |
| Net income 1 | -55.74 | -32.13 | -105.5 | -119.2 | -106.8 | -217.5 | -260.5 | -249.9 |
| Net margin | -130.44% | -75.2% | -170.55% | -175.89% | -69.47% | -303.17% | -431.68% | -269.64% |
| EPS 2 | -2.430 | -0.9900 | -2.290 | -2.350 | -1.780 | -3.302 | -3.259 | -2.830 |
| Free Cash Flow 1 | -68.5 | -74.93 | -97 | -4.309 | - | -238.7 | -227.3 | -199.5 |
| FCF margin | -160.3% | -175.39% | -156.76% | -6.36% | - | -332.72% | -376.73% | -215.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/18/21 | 2/28/22 | 3/30/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.517 | 10.65 | 5.897 | 28.1 | 25.15 | 8.632 | 12.67 | 10.41 | 16.92 | 113.7 | 10.73 | 20.27 | 8.885 | 10.34 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -34.67 | -35.04 | -39.13 | -19.38 | -21.21 | -49.22 | -42.24 | -46.18 | -44.01 | 43.15 | -57.25 | -48.09 | -61.98 | -63.76 | -72 |
| Operating Margin | -407.12% | -328.85% | -663.59% | -68.97% | -84.34% | -570.23% | -333.26% | -443.52% | -260.07% | 37.95% | -533.65% | -237.32% | -697.63% | -616.38% | -2,400% |
| Earnings before Tax (EBT) 1 | -30.9 | -38.12 | -39.11 | -23.51 | -19.49 | -34.59 | -49.66 | -38.37 | -47.44 | 46.87 | -58.44 | -48.7 | -62.78 | -64.69 | -73.3 |
| Net income 1 | -30.9 | -38.12 | -39.11 | -26.01 | -19.49 | -34.59 | -50.05 | -38.52 | -49.28 | 31.06 | -58.51 | -48.77 | -62.85 | -64.77 | -73.3 |
| Net margin | -362.83% | -357.85% | -663.22% | -92.58% | -77.5% | -400.76% | -394.9% | -370% | -291.21% | 27.32% | -545.38% | -240.66% | -707.36% | -626.08% | -2,443.33% |
| EPS 2 | -0.6700 | -0.8300 | -0.8400 | -0.5500 | -0.3700 | -0.6100 | -0.8500 | -0.6400 | -0.8100 | 0.5200 | -0.9298 | -0.7633 | -0.9377 | -0.9327 | -0.8550 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/8/22 | 3/30/23 | 5/15/23 | 8/10/23 | 11/13/23 | 3/25/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 108 | - | 137 | 285 | - | 164 | 368 | 163 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -68.5 | -74.9 | -97 | -4.31 | - | -239 | -227 | -199 |
| ROE (net income / shareholders' equity) | -48.6% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -29.4% | - | - | - | - | -72% | -80.4% | -82% |
| Assets 1 | 189.8 | - | - | - | - | 302.1 | 324 | 304.9 |
| Book Value Per Share 2 | 4.230 | - | - | - | - | -0.9500 | 0.7400 | -0.7200 |
| Cash Flow per Share 2 | -2.830 | - | - | - | - | -3.330 | -1.410 | -1.500 |
| Capex 1 | 3.48 | 7.13 | 15.3 | 7.86 | - | 7.39 | 7.26 | 6.26 |
| Capex / Sales | 8.15% | 16.69% | 24.76% | 11.59% | - | 10.3% | 12.03% | 6.75% |
| Announcement Date | 3/16/20 | 3/18/21 | 2/28/22 | 3/30/23 | 3/25/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.42
USD
Average target price
12.89
USD
Spread / Average Target
+276.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.28% | 263M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- STRO Stock
- Financials Sutro Biopharma, Inc.
